RUA Life Sciences plc (RUA.L)
LSE · GBp · Healthcare · Medical Devices
£27.50 (+0.00%) as of
Key statistics
- Market cap
- 17.07M
- Forward P/E
- -68.75
- EPS (TTM)
- 0.00
- Dividend yield
- 0.00%
- 52-week range
- 10.50 – 31.00
- Beta
- 1.00
- Revenue (TTM)
- 4.62M
- Profit margin
- 6.10%
- Analyst target
- £50.00
- Volume
- 91.34k
About RUA Life Sciences plc
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and services of medical device, as well as implantable fabric. It also engages in the development and commercialization of bore polymer sealed grafts and soft tissue patches; and development of tri-leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Irvine, United Kingdom
- Employees
- 59
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.